Silibinin inhibits proliferation, induces apoptosis and causes cell cycle arrest in human gastric cancer MGC803 cells via STAT3 pathway inhibition

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 16, 2014, Pages 6791-6798

  Wang, Yi Xin ^a   Cai, Hong ^a   Jiang, Gang ^a   Zhou, Tian Bao ^b   Wu, Hai ^c  

^a SICHUAN CANCER HOSPITAL   (China)

^b NINGBO FIRST HOSPITAL   (China)

^c SUINING CENTRAL HOSPITAL   (China)

Author keywords

Apoptosis; Cell cycle arrest; Gastric cancer; Silibinin; STAT3 pathway

Indexed keywords

ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; BIRC5 PROTEIN, HUMAN; CASPASE 3; CASPASE 9; CCNB1 PROTEIN, HUMAN; CDK1 PROTEIN, HUMAN; CYCLIN B1; CYCLIN DEPENDENT KINASE; INHIBITOR OF APOPTOSIS PROTEIN; MCL1 PROTEIN, HUMAN; MESSENGER RNA; PROTEIN BCL X; PROTEIN MCL 1; SILIBININ; SILYMARIN; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; DRUG EFFECTS; GENETICS; HUMAN; M PHASE CELL CYCLE CHECKPOINT; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN B1; CYCLIN-DEPENDENT KINASES; DOWN-REGULATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; M PHASE CELL CYCLE CHECKPOINTS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; RNA, MESSENGER; SILYMARIN; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS;

EID: 84924934348     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.16.6791     Document Type: Article

References (81)

1. Agarwal C, Singh RP, Dhanalakshmi S, et al (2003). Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene, 22, 8271-82.
2. Ahmad A, Sarkar SH, Aboukameel A, et al (2012). Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling. Carcinogenesis, 33, 2450-6.
3. Ambrosini G, Adida C, Altieri DC (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med, 3, 917-21.
4. Bollrath J, Phesse TJ, von Burstin VA, et al (2009). gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell, 15, 91-102.
5. Chen XL, Chen XZ, Yang C, et al (2013). Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxanecontaining palliative chemotherapy for gastric carcinoma, a systematic review and meta-analysis. PLoS One, 8, 60320.
6. Chetty C, Dontula R, Ganji PN, Gujrati M, Lakka SS (2012). SPARC expression induces cell cycle arrest via STAT3 signaling pathway in medulloblastoma cells. Biochem Biophys Res Commun, 417, 874-9.
7. Cheung CW, Gibbons N, Johnson DW, Nicol DL (2010). Silibinin-a promising new treatment for cancer. Anticancer Agents Med Chem, 10, 186-95.
8. Cufi S, Bonavia R, Vazquez-Martin A, et al (2013). Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFRmutant non-small-cell lung carcinoma cells. Food Chem Toxicol, 60, 360-8.
9. Cui JW, Li Y, Wang C, Cheng Y, Wei L (2012). Knockdown of a proliferation-inducing ligand (PRIL) suppresses the proliferation of gastric cancer cells. Asian Pac J Cancer Prev, 13, 633-36.
10. Deep G, Agarwal R (2010). Antimetastatic efficacy of silibinin, molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev, 29, 447-63.
11. Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R (2006). Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells, A comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene, 25, 1053-69.
12. Devarajan E, Huang S (2009). STAT3 as a central regulator of tumor metastases. Curr Mol Med, 9, 626-33.
13. Ding BB, Yu JJ, Yu RY, et al (2008). Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood, 111, 1515-23.
14. Ececen T, Dost N, Culhaci A, et al (2011). Protective effects of silymarin against doxorubicin-induced toxicity. Asian Pac J Cancer Prev, 12, 2697-704
15. Féher J, Lengyel G (2012). Silymarin in the prevention and treatment of liver diseases and primary liver cancer. Curr Pharm Biotechnol, 13, 210-7.
16. Fischer U, Schulze-Osthoff K (2005). New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev, 57, 187-215.
17. Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA (2011). Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer, 11, 125.
18. Ghasemi R, Ghaffari SH, Momeny M, et al (2013). Multitargeting and antimetastatic potentials of silibinin in human HepG-2 and PLC/PRF/5 Hepatoma cells. Nutr Cancer, 65, 590-9.
19. Ghobrial IM, Witzig TE, Adjei AA (2005). Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin, 55, 178-94.
20. Giraud AS, Menheniott TR, Judd LM (2012). Targeting STAT3 in gastric cancer. Expert Opin Ther Targets, 16, 889-901.
21. Gritsko T, Williams A, Turkson J, et al (2006). Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res, 12, 11-9.
22. Hogan FS, Krishnegowda NK, Mikhailova M, Kahlenberg MS (2007). Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J Surg Res, 143, 58-65.
23. Hsu KW, Hsieh RH, Huang KH, et al (2012). Activation of the Notch1/STAT3/Twist signaling axis promotes gastric cancer progression. Carcinogenesis, 33, 1459-67.
24. Huang C, Huang R, Chang W, et al (2012). The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma. Neoplasma, 59, 52-61.
25. Huang S, Chen M, Shen Y, et al (2012). Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett, 315, 198-205.
26. Huang WW, Yang JS, Lin MW, et al (2012). Cucurbitacin E induces G (2)/M phase arrest through STAT3/p53/p21 signaling and provokes apoptosis via Fas/CD95 and mitochondria-dependent pathways in human bladder cancer T24 cells. Evid Based Complement Alternat Med, 2012, 952762.
27. Hunter AM, LaCasse EC, Korneluk RG (2007). The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis, 12, 1543-68.
28. Kang MH, Reynolds CP (2009). Bcl-2 inhibitors, targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res, 15, 1126-32.
29. Karpeh MS Jr (2013). Palliative treatment and the role of surgical resection in gastric cancer. Dig Surg, 30, 174-80.
30. Kaur M, Velmurugan B, Tyagi A, et al (2009). Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft. Mol Cancer Ther, 8, 2366-74.
31. Kazem NK, Abolfazl A, Mohammad PM, Alireza A, Hassan D (2013). Inhibition of leptin and leptin receptor gene expression by silibinin-curcumin combination. Asian Pac J Cancer Prev, 14, 6595-99.
32. Kim DY, Cha ST, Ahn DH, et al (2009). STAT3 expression in gastric cancer indicates a poor prognosis. J Gastroenterol Hepatol, 24, 646-51.
33. Kujawski M, Kortylewski M, et al (2008). Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest, 118, 3367-77.
34. Lee SW, Ahn YY, Kim YS, et al (2012). The Immunohistochemical Expression of STAT3, Bcl-xL, and MMP-2 Proteins in Colon Adenoma and Adenocarcinoma. Gut Liver, 6, 45-51.
35. Leung WK, Wu MS, Kakugawa Y (2008). Asia pacific working group on gastric cancer. screening for gastric cancer in Asia, current evidence and practice. Lancet Oncol, 9, 279-87.
36. Li L, Zeng J, Gao Y, He D (2010). Targeting silibinin in the antiproliferative pathway. Expert Opin Investig Drugs, 19, 243-55.
37. Lin CJ, Sukarieh R, Pelletier J (2009). Silibinin inhibits translation initiation, implications for anticancer therapy. Mol Cancer Ther, 8, 1606-12.
38. Lin CM, Chen YH, Ma HP, et al (2012). Silibinin inhibits the invasion of IL-6-stimulated colon cancer cells via selective JNK/AP-1/MMP-2 modulation in vitro. J Agric Food Chem, 60, 12451-7.
39. Liu DB, Hu GY, Long GX, Qiu H, Mei Q, Hu GQ (2012). Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. Acta Pharmacol Sin, 33, 682-90.
40. Lu W, Lin C, King TD, Chen H, Reynolds RC, Li Y (2012). Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells. Cell Signal, 24, 2291-6.
41. Malumbres M, Barbacid M (2009). Cell cycle, CDKs and cancer, a changing paradigm. Nat Rev Cancer, 9, 153-66
42. Marzieh N, Nosratollah Z, Kazem NK, Mahdieh M (2013). Curcumin and silibinin inhibit telomerase expression in T47D human breast cancer cells. Asian Pac J Cancer Prev, 14, 3449-53.
43. Masuda H, Fong CS, Ohtsuki C, Haraguchi T, Hiraoka Y (2011). Spatiotemporal regulations of Wee1 at the G2/M transition. Mol Biol Cell, 22, 555-69.
44. Masuda M, Suzui M, Yasumatu R, et al (2002). Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res, 62, 3351-5.
45. Mateen S, Raina K, Agarwal R (2013). Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer. Nutr Cancer, 65, 3-11.
46. Mateen S, Raina K, Jain AK, et al (2012). Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells. Epigenetics, 7, 1161-72.
47. Mateen S, Tyagi A, Agarwal C, Singh RP, Agarwal R (2010). Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators. Mol Carcinog, 49, 247-58.
48. McDonald ER 3rd, El-Deiry WS (2000). Cell cycle control as a basis for cancer drug development (Review). Int J Oncol, 16, 871-86.
49. Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008). Survivin, key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res, 14, 5000-5.
50. Morikawa T, Baba Y, Yamauchi M, et al (2011). STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res, 17, 1452-62.
51. Niu G, Wright KL, Huang M, et al (2002). Constitutive Stat3 activity upregulates VEGF expression and tumor angiogenesis. Oncogene, 21, 2000-8.
52. Oh SJ, Jung SP, Han J, et al (2013). Silibinin inhibits TPAinduced cell migration and MMP-9 expression in thyroid and breast cancer cells. Oncol Rep, 29, 1343-8.
53. Olivier G, Jonathon P (2010). Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev Cell, 18, 533-43.
54. Owa T, Yoshino H, Yoshimatsu K, Nagasu T (2001). Cell cycle regulation in the G1 phase, a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem, 8, 1487-503.
55. Park MT, Lee SJ (2003). Cell cycle and cancer. J Biochem Mol Biol, 36, 60-5.
56. Quoc Trung L, Espinoza JL, Takami A, Nakao S (2013). Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibition. PLoS One, 8, 55183.
57. Rajamanickam S, Velmurugan B, Kaur M, Singh RP, Agarwal R (2010). Chemoprevention of intestinal tumorigenesis in APCmin/+ mice by silibinin. Cancer Res, 70, 2368-78.
58. Santamaria D, Ortega S (2006). Cyclins and CDKS in development and cancer, lessons from genetically modified mice. Front Bio Sci, 11, 1164-88.
59. Sato T, Neilson LM, Peck AR, et al (2011). Signal transducer and activator of transcription-3 and breast cancer prognosis. Am J Cancer Res, 1, 347-55.
60. Schwartz GK (2002). CDK inhibitors, cell cycle arrest versus apoptosis. Cell Cycle, 1, 122-3.
61. Shi ZB, Zhao D, Huang YY, et al (2012). Discovery, synthesis, and evaluation of small-molecule signal transducer and activator of transcription 3 inhibitors. Chem Pharm Bull (Tokyo), 60, 1574-80.
62. Singh N, Hussain S, Bharadwaj M, et al (2012). Overexpression of signal transducer and activator of transcription (STAT-3 and STAT-5) transcription factors and alteration of suppressor of cytokine signaling (SOCS-1) protein in prostate cancer. J Recept Signal Transduct Res, 32, 321-7.
63. Singh RP, Agarwal R (2004). Prostate cancer prevention by silibinin. Curr Cancer Drug Targets, 4, 1-11.
64. Stephanou A, Brar BK, Knight RA, Latchman DS (2000). Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ, 7, 329-30.
65. Sun M, Liu C, Nadiminty N, et al (2012). Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. Prostate, 72, 82-9.
66. Taylor WR, Stark GR (2001). Regulation of the G2/M transition by p53. Oncogene, 20, 1803-15.
67. Tyagi A, Agarwal C, Agarwal R (2002). The cancer preventive flavonoid silibinin causes hypophosphorylation of Rb/p107 and Rb2/p130 via modulation of cell cycle regulators in human prostate carcinoma DU145 cells. Cell Cycle, 1, 137-42.
68. Tyagi A, Agarwal C, Harrison G, Glode LM, Agarwal R (2004). Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKICDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis, 25, 1711-20.
69. Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R (2002). Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin Cancer Res, 8, 3512-9.
70. Van Cutsem E, Van de Velde C, Roth A (2008). European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer, 44, 182-94.
71. Verschoyle RD, Greaves P, Patel K, et al (2008). Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis, relationship with silibinin levels. Eur J Cancer, 44, 898-906.
72. Wang J, Chen S, Xu S, et al (2012). In vivo induction of apoptosis by fucoxanthin, a marine carotenoid, associated with downregulating STAT3/EGFR signaling in sarcoma 180 (S180) xenografts-bearing mice. Mar Drugs, 10, 2055-68.
73. Wang YJ, Niu XP, Li Y, Zhen H, Ma YJ (2013). Effects of celecoxib on cycle kinetics of gastric cancer cells and protein expression of cytochrome c and caspase-9. Asian Pac J Cancer Prev, 14, 2343-47.
74. Williams GH, Stoeber K (2012). The cell cycle and cancer. J Pathol, 226, 352-64.
75. Wu KJ, Zeng J, Zhu GD, et al (2009). Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacol Sin, 30, 1162-8.
76. Xiong H, Du W, Wang JL, et al (2012). Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer. J Mol Med (Berl), 90, 1037-46.
77. Yakata Y, Nakayama T, Yoshizaki A, et al (2007). Expression of p-STAT3 in human gastric carcinoma, significant correlation in tumour invasion and prognosis. Int J Oncol, 30, 437-42.
78. Yang C, Lee H, Pal S, et al (2013). B cells Promote tumor progression via STAT3 regulated-angiogenesis. PLoS One, 8, 64159.
79. Yi Qin, Jing Chen, Li Li (2012). Exogenous morphine inhibits human gastric cancer MGC-803 cell growth by cell cycle arrest and apoptosis induction. Asian Pac J Cancer Prev, 13, 1377-82.
80. Zhang HQ, He B, Fang N (2013). Autophagy inhibition sensitizes cisplatin cytotoxicity in human gastric cancer cell line sgc7901. Asian Pac J Cancer Prev, 14, 4685-88.
81. Zhang X, Yue P, Page BD, et al (2012). Orally bioavailable smallmolecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci USA, 109, 9623-8.